Our analysts just identified a stock with the potential to be the next Nvidia. Management is pivoting the business from an investment phase to a compounding growth phase, centered on four drivers: account depth, distribution efficiency, AI leverage, and value chain participation. Performance attribution for the quarter was impacted by the strategic decision to exit pharmaceutical services revenue in favor of higher-quality, recurring B2B2C revenue streams. A structural shift toward channel-enabled distribution has resulted in 75% of new accounts coming through partners, significantly lowering customer acquisition costs and shortening sales cycles. The company's vertical integration—owning hardware, data, and AI—serves as a competitive moat, with 13 billion proprietary data points powering personalized clinical interventions via DarioIQ.